← All trials
NCT02467842
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2014
- Primary completion
- Dec 1, 2014
- Completion date
- May 1, 2015
- First posted
- —
- Last posted
- —
- Enrollment
- 1503
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- SK ChemicalsLead sponsor
- Korea UniversityOverall official - principal investigator
- Chonnam National UniversityOverall official - principal investigator
- Chungbuk National UniversityOverall official - principal investigator
- Chungnam National UniversityOverall official - principal investigator
- Hallym UniversityOverall official - principal investigator
- Kyungpook UniversityOverall official - principal investigator
- Korea UniversityStudy chair
- Inha UniversityOverall official - principal investigator
- Katholieke Universiteit LeuvenOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.